Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series

Abstract

Erythrodermic psoriasis (EP) is a rare but severe variant of psoriasis. Evidence-based treatment of EP is limited due to its rarity and lack of controlled studies. Secukinumab is an anti-IL17A monoclonal antibody approved for the treatment of moderate to severe psoriasis with superior efficacy compared to etanercept and ustekinumab. Since 2015 it has been approved by FDA in the United States and gained increasing popularity for the treatment of plaque psoriasis. However, there are very few reports showing secukinumab as an option for treating EP.

This article is protected by copyright. All rights reserved.